PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis

PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis

Abstract Background We present a systematic review and meta‐analysis of randomized clinical trials (RCTs) with PARPi either as monotherapy or in combination with an androgen receptor‐targeted agent (ARTA) in first‐ and second‐line settings. Methods Primary endpoints are radiographic progression free...

Full description

Saved in:
Bibliographic Details
Main Authors: Michela Roberto, Mattia Alberto Di Civita, Daniele Marinelli, Andrea Torchia, Nertila Cara, Giulia Maltese, Iolanda Speranza, Daniele Santini
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:BJUI Compass
Subjects:
androgen receptor signalling inhibitor (ARSI)
androgen receptor‐targeted agents (ARTA)
BRCA
DNA damage repair defects (DDR)
homologous recombination repair (HRR)
poly‐ADP ribose polymerase (PARP) inhibitors
Online Access:https://doi.org/10.1002/bco2.455
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/bco2.455

Similar Items